Click here: to donate by Credit Card
Or here: to donate by PayPal
Or by mail to: Free Republic, LLC - PO Box 9771 - Fresno, CA 93794
Thank you very much and God bless you.
Posted on 05/10/2025 11:17:41 AM PDT by SoConPubbie
President Donald J. Trump is determined to make the American pharmaceutical and biotechnology industries great again — both as a matter of national security and to unleash unprecedented prosperity for American workers.
Gilead Sciences became the latest industry leader to announce a massive new investment in its U.S. operations with an $11 billion boost to its planned U.S.-based spending.
The company joins a host of others in expanding their domestic footprint to align with President Trump’s vision:
Click here: to donate by Credit Card
Or here: to donate by PayPal
Or by mail to: Free Republic, LLC - PO Box 9771 - Fresno, CA 93794
Thank you very much and God bless you.
Good
It is absolutely necessary. Every drug for every common and chronic disease should be made here, even generics.
How we ever allowed drug manufacturing to move overseas is a mystery to me.
It’s like allowing defense manufacturing to move overseas. If there’s a war you’ll be cut off.
Drugs are an essential industry and should be on-shored as much as possible.
Will this also include precursor chemicals used in the manufacture or pharmaceuticals?
MAHA
I wonder why we let the generic drug and medical supply manufacturing relocate out of Puerto Rico years ago? We should have kept it and could use bringing it back there too.
Novo Nordisk is investing another $4.1 billion in a new fill-finish facility in Clayton, North Carolina, to expand its U.S. manufacturing capacity. This investment aims to increase production of its weight loss drug Wegovy and diabetes medication Ozempic, and create 1,000 new jobs.
In 2024, Novo Nordisk increased actual investments in production and plans to invest approx USD 6.8 billion in new production compared to actual investments of USD 3.9 last year to increase supply.
2,500 Novo Nordisk employees are already working in the region after the several billion dollar investment in facilities to produce Ozembic.
My daughter worked with the Novo Nordisk engineers during construction of the new facility and switched to production when the facility construction was finished. Her speciality, quality control in robotic pharmaceutical production.
I wonder why we let the generic drug and medical supply manufacturing relocate out of Puerto Rico years ago? We should have kept it and could use bringing it back there too.
**************************************************
(After a quick poke)....
Section 936 went away. It was basically tax exemptions. Drug and other manufacturers left for better taxes.
Puerto Rico been in a recession since.
Most of those do not sound like they are bringing back anything. They sound like things that have already been planned at existing facilities and would have happened no matter who was President. We need to actually get manufacturing to relocate from foreign countries to the US, that is “bringing back”.
Tax breaks for PR went away. Also, PR has hurricanes and earthquakes that wreak havoc on their infrastructure.
Better news would be looking into why there are only THREE companies that make it.
No one was ever going to war again because we would all be dependent on each other in our "global village".
Not a great plan.
Is it just inflation?
In the past few weeks we have read about many companies saying they will be building multi-billion dollar facilities in the USA.
It was not that long ago that a $1 Billion capital expenditure by a company was a really big deal.
Corporate weasels wouldn’t do it without being forced.
https://upload.wikimedia.org/wikipedia/commons/9/99/JohnsonJohnson_HQ_building.jpg
See, I is real Guud at the Engrifs language if I type whatever twice…
Geez…
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.